341 related articles for article (PubMed ID: 35008414)
21. Metformin induces CD11b+-cell-mediated growth inhibition of an osteosarcoma: implications for metabolic reprogramming of myeloid cells and anti-tumor effects.
Uehara T; Eikawa S; Nishida M; Kunisada Y; Yoshida A; Fujiwara T; Kunisada T; Ozaki T; Udono H
Int Immunol; 2019 Mar; 31(4):187-198. PubMed ID: 30508092
[TBL] [Abstract][Full Text] [Related]
22. Metabolic reprograming of tumor-associated macrophages.
Puthenveetil A; Dubey S
Ann Transl Med; 2020 Aug; 8(16):1030. PubMed ID: 32953830
[TBL] [Abstract][Full Text] [Related]
23. Tumor-Associated Macrophages and Myeloid-Derived Suppressor Cells as Immunosuppressive Mechanism in Ovarian Cancer Patients: Progress and Challenges.
Okła K; Wertel I; Polak G; Surówka J; Wawruszak A; Kotarski J
Int Rev Immunol; 2016 Sep; 35(5):372-385. PubMed ID: 27644763
[TBL] [Abstract][Full Text] [Related]
24. Immunometabolic attributes and mitochondria-associated signaling of Tumor-Associated Macrophages in tumor microenvironment modulate cancer progression.
Dubey S; Ghosh S; Goswami D; Ghatak D; De R
Biochem Pharmacol; 2023 Feb; 208():115369. PubMed ID: 36481347
[TBL] [Abstract][Full Text] [Related]
25. Pancreatic Tumor Microenvironment.
Wang K; He H
Adv Exp Med Biol; 2020; 1296():243-257. PubMed ID: 34185297
[TBL] [Abstract][Full Text] [Related]
26. Lipid Metabolic Regulatory Crosstalk Between Cancer Cells and Tumor-Associated Macrophages.
Liu S; Shen YY; Yin LY; Liu J; Zu X
DNA Cell Biol; 2023 Aug; 42(8):445-455. PubMed ID: 37535386
[TBL] [Abstract][Full Text] [Related]
27. Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment.
Olsson A; Nakhlé J; Sundstedt A; Plas P; Bauchet AL; Pierron V; Bruetschy L; Deronic A; Törngren M; Liberg D; Schmidlin F; Leanderson T
J Immunother Cancer; 2015; 3():53. PubMed ID: 26673090
[TBL] [Abstract][Full Text] [Related]
28. Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers.
Fujimura T; Aiba S
Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32707850
[TBL] [Abstract][Full Text] [Related]
29. Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8
Liu C; Chikina M; Deshpande R; Menk AV; Wang T; Tabib T; Brunazzi EA; Vignali KM; Sun M; Stolz DB; Lafyatis RA; Chen W; Delgoffe GM; Workman CJ; Wendell SG; Vignali DAA
Immunity; 2019 Aug; 51(2):381-397.e6. PubMed ID: 31350177
[TBL] [Abstract][Full Text] [Related]
30. Tumor Microenvironment and Nitric Oxide: Concepts and Mechanisms.
Vedenko A; Panara K; Goldstein G; Ramasamy R; Arora H
Adv Exp Med Biol; 2020; 1277():143-158. PubMed ID: 33119871
[TBL] [Abstract][Full Text] [Related]
31. Friend or Foe? Recent Strategies to Target Myeloid Cells in Cancer.
Chaib M; Chauhan SC; Makowski L
Front Cell Dev Biol; 2020; 8():351. PubMed ID: 32509781
[TBL] [Abstract][Full Text] [Related]
32. The Role of Tumor Associated Macrophages (TAMs) in Cancer Progression, Chemoresistance, Angiogenesis and Metastasis - Current Status.
Dallavalasa S; Beeraka NM; Basavaraju CG; Tulimilli SV; Sadhu SP; Rajesh K; Aliev G; Madhunapantula SV
Curr Med Chem; 2021; 28(39):8203-8236. PubMed ID: 34303328
[TBL] [Abstract][Full Text] [Related]
33. New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs.
Lakshmanachetty S; Cruz-Cruz J; Hoffmeyer E; Cole AP; Mitra SS
Cells; 2021 Apr; 10(4):. PubMed ID: 33919732
[TBL] [Abstract][Full Text] [Related]
34. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
35. Myeloid-Derived Suppressor Cells in Immune Microenvironment Promote Progression of Esophagogastric Junction Adenocarcinoma.
Wang Y; Sun H; Zhu N; Wu X; Sui Z; Gong L; Yu Z
Front Oncol; 2021; 11():640080. PubMed ID: 33854974
[TBL] [Abstract][Full Text] [Related]
36. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
De Cicco P; Ercolano G; Ianaro A
Front Immunol; 2020; 11():1680. PubMed ID: 32849585
[TBL] [Abstract][Full Text] [Related]
37. Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy.
Wegiel B; Vuerich M; Daneshmandi S; Seth P
Front Oncol; 2018; 8():284. PubMed ID: 30151352
[TBL] [Abstract][Full Text] [Related]
38. Targeting tumor-associated macrophages in the tumor microenvironment.
Zhou K; Cheng T; Zhan J; Peng X; Zhang Y; Wen J; Chen X; Ying M
Oncol Lett; 2020 Nov; 20(5):234. PubMed ID: 32968456
[TBL] [Abstract][Full Text] [Related]
39. Metabolic changes in tumor cells and tumor-associated macrophages: A mutual relationship.
Netea-Maier RT; Smit JWA; Netea MG
Cancer Lett; 2018 Jan; 413():102-109. PubMed ID: 29111350
[TBL] [Abstract][Full Text] [Related]
40. Tumor-promoting myeloid cells in the pathogenesis of human oncoviruses: potential targets for immunotherapy.
Aghamajidi A; Farhangnia P; Pashangzadeh S; Damavandi AR; Jafari R
Cancer Cell Int; 2022 Oct; 22(1):327. PubMed ID: 36303138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
